Medicare’s new $50 GLP‑1 weight‑loss drug program may create barriers for patients, warns experts

Medicare has launched a program that caps out‑of‑pocket costs for GLP‑1 weight‑loss medicines such as Wegovy, Zepbound and Foundayo at $50 a month for eligible beneficiaries. The initiative is intended to make these high‑impact treatments more affordable.

Eligibility, however, is tied to a detailed checklist that includes specific body‑mass‑index thresholds and combinations of chronic conditions. The complexity of the criteria could lead to confusion among patients and primary‑care doctors, potentially causing interruptions in therapy.

Jeffrey Millstein, an internist at Penn Medicine, argues that the well‑meaning policy may inadvertently restrict access at a time when broader coverage of GLP‑1 drugs is needed, creating a barrier rather than a bridge for patients seeking weight‑loss treatment.